BioMarin Pharmaceutical Profile

USD 0.97  0.95%

Sale by Henry Fuchs of 834 shares of BioMarin Pharmaceutical

BioMarin Pharmaceutical insider trading alert for sale of common stock by Henry Fuchs, EVP Chief Medical Officer, on July 21, 2018. This event was filed by Biomarin Pharmaceutical I with SEC on 2011-03-02. Statement of changes in beneficial ownership - SEC Form 4. Henry Fuchs is currently serves as executive vice president and chief medical officer of BioMarin Pharmaceutical [view details]   

BioMarin Pharmaceutical Summary

BioMarin Pharmaceutical (BMRN) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 2,581 people. BioMarin Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 18.36 B. BioMarin Pharmaceutical conducts business under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 176.71 M outstanding shares of which 11.71 M shares are currently shorted by private and institutional investors with about 8.57 trading days to cover. BIOMARIN PHARMACE currently holds about 1.38 B in cash with 19.09 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.82.
Check BioMarin Pharmaceutical Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 102.87HorizonTargetOdds Above 102.87
86.45%30 days 102.87 13.39%
Based on normal probability distribution, the odds of BioMarin Pharmaceutical to move above current price in 30 days from now is about 13.39% (This BioMarin Pharmaceutical probability density function shows the probability of BioMarin Pharmaceutical Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Manning Napier Group LlcCommon Shares1.9 M177.4 M
Fred Alger Management IncCommon Shares974.5 K91.8 M
Calamos Advisors LlcDebt46.5 M55.1 M
View BioMarin Pharmaceutical Diagnostics

Selected BioMarin Pharmaceutical Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

BioMarin Pharmaceutical Against Markets

Current Ratings

BioMarin Pharmaceutical 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for BioMarin Pharmaceutical are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was founded in 1996 and is headquartered in San Rafael, California. BioMarin Pharmaceutical operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 2581 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
BioMarin Pharmaceutical SEC Filings
BioMarin Pharmaceutical SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameBioMarin Pharmaceutical
Chairman of the Board, CEOJeanJacques BienaimeView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business Address770 Lindaro Street
Foreign Associate  Austria
ExchangeBATS Exchange
CIK Number0001048477
IndustryPharmaceuticals And Biosciences
Phone415 506 6700
CurrencyUSD - US Dollar

Did you try this?

Run Correlation Analysis Now

Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Correlation Analysis

BioMarin Pharmaceutical Corporate Directors

Elaine Heron Independent Director
Dennis Slamon Director
Robert Hombach Independent Director
Check also Trending Equities. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.